Bimekizumab
- Generic Name
- Bimekizumab
- Brand Names
- Bimzelx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418205-77-2
- Unique Ingredient Identifier
- 09495UIM6V
- Background
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 inhibitor) and adalimumab (a TNF inhibitor) in the treatment of moderate-to-severe psoriasis, likely owing to its dual inhibition of both IL-17A and IL-17F. Bimekizumab was also granted FDA approval on October 18, 2023.
- Indication
Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
UCB Gets FDA Approval for Bimzelx for Hidradenitis Suppurativa
Bloomberg connects decision makers to a dynamic network for business and financial information, news, and insights globally.
UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and ...
UCB announces FDA approval of BIMZELX® (bimekizumab-bkzx) for moderate to severe hidradenitis suppurativa (HS), the first medicine to selectively inhibit IL-17F and IL-17A. Phase 3 studies showed deep and sustained clinical responses up to 48 weeks, addressing substantial unmet needs in HS treatment.
UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa
UCB's Bimzelx (bimekizumab-bkzx) receives FDA approval as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa (HS). Bimzelx demonstrated deep and sustained clinical responses in Phase 3 studies, addressing significant unmet needs in HS treatment.
UCB Receives U.S. FDA Approval for BIMZELX
UCB's BIMZELX® (bimekizumab-bkzx) received FDA approval for treating moderate-to-severe hidradenitis suppurativa (HS) in adults, marking its fifth U.S. indication. Supported by Phase 3 studies BE HEARD I and II, BIMZELX showed sustained clinical responses up to 48 weeks, offering a new treatment option for HS patients.
UCB Receives U.S. FDA Approval for BIMZELX®
BIMZELX® (bimekizumab-bkzx) approved by FDA for moderate-to-severe hidradenitis suppurativa (HS) treatment, showing sustained improvement in symptoms from Week 16 to 48 in Phase 3 studies BE HEARD I and II. HS is a chronic, painful inflammatory skin disease. BIMZELX targets IL-17A and IL-17F, marking its fifth U.S. indication.
Two-Year Phase III Data Confirm Long-Term Efficacy, Safety of Bimzelx in Psoriatic Arthritis
Two-year data from Phase III trials and extensions show Bimzelx (bimekizumab-bkzx) maintains efficacy and safety in treating PsA, nr-axSpA, and AS by inhibiting IL-17A and IL-17F, with high response rates sustained over two years.
UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for treating adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis
UCB announced FDA approval of BIMZELX® (bimekizumab-bkzx) for treating adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. BIMZELX® is the first treatment targeting IL-17A and IL-17F cytokines, offering a new option for chronic inflammatory diseases. Dosage is 160 mg every four weeks, with clinical responses sustained up to 52 weeks.
UCB receives U.S. FDA approval for BIMZELX [®] (bimekizumab-bkzx) as a treatment for adults with moderate to severe hidradenitis suppurativa
UCB announced FDA approval of BIMZELX® (bimekizumab-bkzx) for treating adults with moderate to severe hidradenitis suppurativa (HS), marking it as the first medicine targeting IL-17A and IL-17F. Supported by Phase 3 studies BE HEARD I and II, it showed significant symptom improvement and sustained clinical responses up to 48 weeks, offering a new treatment option for HS patients.
FDA approves UCB's BIMZELX for multiple inflammatory conditions
The article discusses the use of SSR (Server-Side Rendering) in web development, focusing on its implementation through a specific JavaScript file, 'SSR-service-entry.a83ef302f7dfea8a4b5f.js', which is part of a bundle for rendering views.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath